Kitchener Henry C, Castle Philip E, Cox J Thomas
Academic Unit of Obstetrics & Gynaecology, University of Manchester, St. Mary's Hospital, Whitworth Park, Manchester, UK.
Vaccine. 2006 Aug 31;24 Suppl 3:S3/63-70. doi: 10.1016/j.vaccine.2006.05.113.
This chapter reviews the contribution of cervical cytology, what makes it successful, the management of screen positives and how technological advances may affect its use in the future. Cervical screening has saved hundreds of thousands of lives but has not been available to women in the poorest countries. In countries where wide coverage has been achieved and quality assurance is in place, incidence and death rates have fallen by over 50% even though cervical cytology is logistically complex. The management of high-grade cervical intraepithelial neoplasia (CIN) is very effective, but low-grade cytological abnormalities require care to avoid over-treatment. The increasing rate of human papillomavirus (HPV) testing and the prospect of prophylactic vaccination will change the way cervical cytology is used, possibly giving way to HPV testing as the primary test in secondary prevention.
本章回顾了宫颈细胞学检查的贡献、其成功的原因、筛查阳性结果的处理方法以及技术进步可能如何影响其未来的应用。宫颈筛查挽救了数十万人的生命,但最贫穷国家的妇女无法获得这项服务。在已实现广泛覆盖且有质量保证的国家,尽管宫颈细胞学检查在后勤方面很复杂,但发病率和死亡率已下降了50%以上。高级别宫颈上皮内瘤变(CIN)的处理非常有效,但低级别细胞学异常需要谨慎处理以避免过度治疗。人乳头瘤病毒(HPV)检测率的不断提高以及预防性疫苗接种的前景将改变宫颈细胞学检查的使用方式,HPV检测可能会取代它成为二级预防的主要检测方法。